3 news items
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GLYC
6 May 24
call and webcast today at 8:30 a.m. ET. To access the call by phone, please go
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
GLYC
27 Mar 24
. To access the call by phone, please go
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
GLYC
13 Mar 24
, 2024 at 8:30 a.m. ET.
To access the call by phone, please go
- Prev
- 1
- Next